Edesa Biotech (EDSA) CEO-linked entity adds 10,000 shares in open-market buy

Rhea-AI Filing Summary

Edesa Biotech CEO-associated entity buys additional shares. On March 5, 2026, Pardeep Nijhawan Medicine Professional Corporation, an entity wholly owned by Edesa Biotech CEO and 10% owner Pardeep Nijhawan, purchased 10,000 common shares of Edesa Biotech at $3.90 per share in an open-market transaction, reported as indirect ownership.

Following this purchase, that corporation held 402,702 common shares. Nijhawan also reported 627,813 common shares held directly, plus additional indirect holdings through The New Nijhawan Family Trust 2015 and several wholly owned entities, while disclaiming beneficial ownership beyond his pecuniary interest in those indirect positions.

Insider Trade Summary

Net Buyer: 10,000 shares ($39,000)

Net Buy 5 txns

Insider Nijhawan Pardeep

Role Chief Executive Officer

Bought 10,000 shs ($39K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	10,000	$3.90	$39K
holding	Common Shares	--	--	--
holding	Common Shares	--	--	--
holding	Common Shares	--	--	--
holding	Common Shares	--	--	--

Holdings After Transaction: Common Shares — 402,702 shares (Indirect, Held by Pardeep Nijhawan Medicine Professional Corporation); Common Shares — 627,813 shares (Direct)

Footnotes (1)

1. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nijhawan Pardeep

(Last) (First) (Middle)

C/O EDESA BIOTECH INC.

100 SPY COURT

(Street)

MARKHAM A6 L3R 5H6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/05/2026		P		10,000	A	$3.9	402,702	I	Held by Pardeep Nijhawan Medicine Professional Corporation(1)
Common Shares								627,813	D
Common Shares								32,609	I	Held by The New Nijhawan Family Trust 2015(1)
Common Shares								32,013	I	Held by The Digestive Health Clinic Inc.(2)
Common Shares								53,104	I	Held by 1968160Ontario Inc.(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

2. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Peter J. Weiler, Attorney-in-Fact for Pardeep Nijhawan	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Edesa Biotech (EDSA) report for Pardeep Nijhawan?

Edesa Biotech reported that an entity wholly owned by CEO Pardeep Nijhawan bought 10,000 common shares at $3.90 per share. The purchase was an open-market transaction and is reported as indirect ownership attributed to Pardeep Nijhawan through his professional corporation.

How many Edesa Biotech (EDSA) shares did the CEO’s corporation hold after the purchase?

After the March 5, 2026 transaction, Pardeep Nijhawan Medicine Professional Corporation held 402,702 Edesa Biotech common shares. These are reported as indirectly owned by CEO Pardeep Nijhawan, who notes that he disclaims beneficial ownership beyond his pecuniary interest in these indirectly held shares.

What are Pardeep Nijhawan’s direct Edesa Biotech (EDSA) share holdings?

The filing shows that, as of the reported date, Pardeep Nijhawan directly held 627,813 Edesa Biotech common shares. This direct position is separate from additional shares held indirectly through his professional corporation, a family trust, and several wholly owned corporate entities.

Which entities hold Edesa Biotech (EDSA) shares indirectly for Pardeep Nijhawan?

Indirect Edesa Biotech holdings are reported through Pardeep Nijhawan Medicine Professional Corporation, The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc. Nijhawan disclaims beneficial ownership of these securities except to the extent of his pecuniary interest in them.

Was the Edesa Biotech (EDSA) CEO’s transaction a buy or a sell?

The reported insider transaction was a buy. Pardeep Nijhawan Medicine Professional Corporation, an entity wholly owned by CEO Pardeep Nijhawan, executed an open-market purchase of 10,000 Edesa Biotech common shares at $3.90 per share, increasing the entity’s indirectly reported holdings.

Why does Pardeep Nijhawan disclaim beneficial ownership of some Edesa Biotech (EDSA) shares?

Nijhawan disclaims beneficial ownership of shares held through his professional corporation, family trust, and related entities except for his pecuniary interest. This standard legal language clarifies that including these shares in the report is not an admission of full beneficial ownership for regulatory purposes.